Epalinges, Switzerland

Jean-Charles Cerrottini


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1999-2002

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Jean-Charles Cerrottini: Innovator in Cancer Research

Introduction

Jean-Charles Cerrottini is a prominent inventor based in Epalinges, Switzerland. He has made significant contributions to the field of cancer research, particularly in the development of immunogenic compositions related to tumor rejection antigens. With a total of 5 patents to his name, Cerrottini's work is pivotal in advancing therapeutic strategies against cancer.

Latest Patents

Cerrottini's latest patents include innovative immunogenic compositions of the tumor rejection antigen precursor MAGE-10. These patents encompass isolated cDNA molecules that encode the tumor rejection antigen precursor MAGE-10, the protein itself, and antibodies specific to it. The applications of these inventions are crucial for developing effective cancer treatments.

Career Highlights

Cerrottini is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to push the boundaries of cancer research. His work has been instrumental in understanding the mechanisms of tumor rejection and the potential for immunotherapy.

Collaborations

Some of his notable coworkers include Donata Rimoldi and Victor Jongeneel, who have collaborated with him on various research projects aimed at enhancing cancer treatment methodologies.

Conclusion

Jean-Charles Cerrottini's contributions to cancer research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in therapeutic approaches to combat cancer effectively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…